GO Therapeutics and Roche collaborate in new glycotargeting bispecific cancer treatment

03:00 EDT 9 Oct 2018 | Bionity

GO Therapeutics, Inc. (GO) announced that it has entered into a license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche). Under the terms of the agreement, GO will grant Roche a worldwide, exclusive license for antibodies generated to address a novel cancer-specific target...

More From BioPortfolio on "GO Therapeutics and Roche collaborate in new glycotargeting bispecific cancer treatment"